Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 14/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964657 | 1.00 | TSHR (0.65) | TSHRHSD17B10KDM4EALDH1A1KMT2A | |
| SCHEMBL1309322 | 0.94 | HSD17B10 (0.66) | TSHRHSD17B10KDM4EALDH1A1KMT2A | |
| SCHEMBL1308249 | 0.93 | HSD17B10 (0.64) | TSHRHSD17B10KDM4EALDH1A1KMT2A | |
| SCHEMBL28734357 | 0.81 | KMT2A (0.65) | ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL29721874 | 0.81 | KMT2A (0.65) | ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL4604120 | 0.80 | ACLY (0.58) | KDM4EALDH1A1GRIK1 | |
| SCHEMBL29183052 | 0.80 | GRIK1 (0.68) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3334201 | 0.79 | HDAC1 (0.67) | KMT2ARAB9A | |
| Bicarbonate SCHEMBL19664773 | 0.79 | RAB9A (0.69) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL4617520 | 0.79 | PRSS12 (0.56) | KDM4EALDH1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | TSHR 4610/4885HSD17B10 1998/4885KDM4E 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.